B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Dong, Qiang ^a   Ma, Xinlong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; TUMOR MARKER; VTCN1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ARTICLE; BONE TISSUE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION; YOUNG ADULT; AGED; BIOSYNTHESIS; BLOOD; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOGENESIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84928966506     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/156432     Document Type: Article

References (24)

1. J. Gill, M. K. Ahluwalia, D. Geller, and R. Gorlick, "New targets and approaches in osteosarcoma, " Pharmacology and Therapeutics, vol. 137, no. 1, pp. 89-99, 2013.
2. S. M. Botter, D. Neri, and B. Fuchs, "Recent advances in osteosarcoma, " Current Opinion in Pharmacology, vol. 16, pp. 15-23, 2014.
3. P. K. Wu, W. M. Chen, O. K. Lee, C. F. Chen, C. K. Huang, and T. H. Chen, "The prognosis for patients with osteosarcoma who have received prior manipulative therapy, " Journal of Bone and Joint Surgery-Series B, vol. 92, no. 11, pp. 1580-1585, 2010.
4. P. Greaves and J. G. Gribben, "The role of B7 familymolecules in hematologic malignancy, " Blood, vol. 121, no. 5, pp. 734-744, 2013.
5. D. V. R. Prasad, S. Richards, X. M. Mai, and C. Dong, "B7S1, a novel B7 family member that negatively regulates T cell activation, " Immunity, vol. 18, no. 6, pp. 863-873, 2003.
6. G. L. Sica, I.-H. Choi, G. Zhu et al., "B7-H4, a molecule of the B7 family, negatively regulates T cell immunity, " Immunity, vol. 18, no. 6, pp. 849-861, 2003.
7. B. Tringler, S. Zhuo, G. Pilkington et al., "B7-H4 is highly expressed in ductal and lobular breast cancer, " Clinical Cancer Research, vol. 11, no. 5, pp. 1842-1848, 2005.
8. S. Salceda, T. Tang, M. Kmet et al., "The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation, " Experimental Cell Research, vol. 306, no. 1, pp. 128-141, 2005.
9. L. Cheng, J. Jiang, R. Gao et al., "B7-H4 expression promotes tumorigenesis in ovarian cancer, " International Journal of Gynecological Cancer, vol. 19, no. 9, pp. 1481-1486, 2009.
10. L. L. Zhang, S. L. Shao, and Y. Wu, "Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance, " Chinese Journal of Cancer, vol. 29, no. 1, pp. 25-29, 2010.
11. Y. Sun, Y. Wang, J. Zhao et al., "B7-H3 and B7-H4 expression in non-small-cell lung cancer, " Lung Cancer, vol. 53, no. 2, pp. 143-151, 2006.
12. Z.-Y. Li, X.-H. Zhang, Y. Chen et al., "Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors, " OncoTargets andTherapy, vol. 6, pp. 869-875, 2013.
13. Y. Chen, H. Zhao, D. Zhu et al., "The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer, " OncoTargets andTherapy, vol. 7, pp. 1465-1472, 2014.
14. T. Arigami, Y. Uenosono, M. Hirata et al., "Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis, " Journal of Surgical Oncology, vol. 102, no. 7, pp. 748-752, 2010.
15. T. Arigami, Y. Uenosono, S. Ishigami, T. Hagihara, N. Haraguchi, and S. Natsugoe, "Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer, " World Journal of Surgery, vol. 35, no. 9, pp. 2051-2057, 2011.
16. M. Fan, Q. Zhuang, Y. Chen et al., "B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma, " International Journal of Clinical and Experimental Pathology, vol. 7, no. 10, pp. 6768-6775, 2014.
17. C. He, H. Qiao, H. Jiang, andX. Sun, "The inhibitory role of B7-H4 in antitumor immunity: association with cancer progression and survival, " Clinical and Developmental Immunology, vol. 2011, Article ID 695834, 8 pages, 2011.
18. I. Simon, S. Zhuo, L. Corral et al., "B7-H4 Is a novel membranebound protein and a candidate serum and tissue biomarker for ovarian cancer, " Cancer Research, vol. 66, no. 3, pp. 1570-1575, 2006.
19. I. Simon, Y. Liu, K. L. Krall et al., "Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer, " Gynecologic Oncology, vol. 106, no. 1, pp. 112-118, 2007.
20. H. Shi, M. Ji, J. Wu et al., "Serum B7-H4 expression is a significant prognostic indicator for patientswith gastric cancer, " World Journal of Surgical Oncology, vol. 12, no. 1, article 188, 2014.
21. R. H. Thompson, X. Zang, C. M. Lohse et al., "Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage, " Cancer Research, vol. 68, no. 15, pp. 6054-6058, 2008.
22. L. Wang, Q. Zhang, W. Chen et al., "B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, " PLoS ONE, vol. 8, no. 8, Article ID e70689, 2013.
23. N. Yu, X. Li, and S. Zheng, "B7-H4's Role 'Beyond the Tumor', " Inflammation, vol. 36, no. 4, pp. 941-947, 2013.
24. A. Rech, C. G. Castro Jr., J. Mattei et al., "Clinical features in osteosarcoma and prognostic implications, " Jornal de Pediatria, vol. 80, no. 1, pp. 65-70, 2004.